Lurbinectedin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Lurbinectedin: From an Unrecorded Original Indication to Multiple Endocrine Neoplasia
One-Sentence Summary
Lurbinectedin (DrugBank ID DB12674) is a DNA-binding/transcription-inhibiting cytotoxic antineoplastic agent; its original approved indication is not recorded in the current evidence pack. The TxGNN model predicts a possible association with Multiple Endocrine Neoplasia, but this signal is currently supported by 0 clinical trials and 0 publications, and the model’s own rationale text states no mechanistic or empirical support was found for this link.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in evidence pack (Data Gap DG002 — MOA also missing) |
| Predicted New Indication | Multiple Endocrine Neoplasia |
| TxGNN Prediction Score | 99.44% |
| Evidence Level | L5 |
| US Market Status | Not marketed (Taiwan: 未上市) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for lurbinectedin is not available in this evidence pack (Data Gap DG002, severity: High). Based on the repurposing rationale text generated alongside the prediction, lurbinectedin is characterized as a DNA-alkylating / transcription-inhibiting cytotoxic antineoplastic agent — consistent with its known pharmacological class.
However, the model’s own rationale explicitly states that no data support a mechanistic link between this cytotoxic, transcription-inhibiting activity and Multiple Endocrine Neoplasia (MEN), an endocrine tumor syndrome. The prediction rests solely on a TxGNN knowledge-graph similarity score (rank 13,032 out of the model’s full output), with no corroborating clinical or literature evidence.
Notably, 9 of the other 10 top-ranked predicted indications for this drug include diseases such as HIV infection, rheumatoid arthritis, ALS, and several veterinary/non-human conditions (feline AIDS, simian immunodeficiency virus infection, bovine rhinotracheitis) — none of which have a plausible pharmacological connection to a cytotoxic antineoplastic agent. This pattern suggests the prediction sits in a low-confidence region of the model’s output space rather than reflecting a biologically grounded signal.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
Lurbinectedin currently has 0 marketing authorizations on record and is not marketed in Taiwan. No license detail is available in the evidence pack.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (DNA alkylating / transcription inhibitor), based on repurposing-rationale description |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Cytotoxic drug handling precautions should be assumed pending confirmation from the official label |
Safety Considerations
Please refer to the package insert for safety information. Note: TFDA label warnings/contraindications are flagged as a Blocking data gap (DG001) — this must be resolved before any safety (S1) evaluation can proceed.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a TxGNN model score (L5, decision stage S0), with zero clinical trials or publications, no confirmed mechanistic rationale, and no original-indication or MOA data on file. The surrounding top-10 predictions include multiple biologically implausible and non-human indications, further weakening confidence in this specific signal.
To proceed, the following is needed:
- TFDA label (warnings/contraindications) — Blocking gap (DG001)
- Confirmed mechanism of action via DrugBank API — High-priority gap (DG002)
- Confirmation of the drug’s original approved indication(s)
- Independent literature or preclinical search specifically for lurbinectedin and endocrine tumor pathways before any further evaluation stage is considered
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.